1. Development of the Live-Attenuated Chikungunya Virus Vaccine Candidate CHIKV-NoLS
- Author
-
Rao, Shambhavi and Rao, Shambhavi
- Abstract
The causal pathogen of chikungunya virus disease, mosquito-transmitted chikungunya virus (CHIKV), has caused significant global epidemics of arthritic disease over the past two decades. A severe chronic, crippling arthritic condition, CHIKV disease can have a negative impact on a patient's mobility and quality of life. Our earlier research led to the production of CHIKV-NoLS, a live-attenuated CHIKV vaccine candidate that has successfully protected against CHIKV disease in preclinical trials. After receiving one dose, mice immunised with CHIKV-NoLS developed a protective immune response against CHIKV. Additional research has shown the utility of a liposome RNA delivery system for directly delivering the RNA genome of CHIKV-NoLS in vivo and promoting in vivo de novo production of live-attenuated vaccine particles.[...] This thesis provides us with essential information about the development of a new vaccine candidate, CHIKV-NoLS, and illustrates how a clinically relevant booster regimen can overcome the challenges faced by a one dose strategy to provide systemic protection against CHIKV disease. Furthermore, I provide new perspectives on the global progress of CHIKV vaccine development to guide future industrial partnerships and clinical development of the CHIKV-NoLS technology. CHIKV-NoLS may be a promising CHIKV vaccine candidate due to lower reversion risks, reported stability, and longevity of protection against CHIKV infection. CHIKV-NoLS faces a long road ahead because no studies on non-human primates or humans have been conducted. Further research on GM cell lines might be useful to establish universal cell lines for vaccine production., Thesis (PhD Doctorate), Doctor of Philosophy (PhD), School of Pharmacy & Med Sci, Griffith Health, Full Text
- Published
- 2023